chrisvoncsefalvay/vaers-outcomes huggingface dataset:
26 minutes after receiving the vaccination, the patient developed  over her left forearm, right shoulder, posterior neck, and left scalp. Upon evaluation, she had no hives or rashes. Lungs were clear on auscultation bilaterally. No shortness of breath, nausea, respiratory distress, anaphylaxis. She was given Allegra 60 mg PO times one. Her blood pressure, taking by machine, was 205/117.  No dizziness, chest pain, headaches, or vision changes. Subsequent manual recheck of her blood pressure were in the 160s to 180/ 100s, and after possibly 30 minutes of monitoring with serial your blood pressure checks, her blood pressure  was 172/94 manually.  Her itching resolved, and she developed no other symptoms.
Severe vomiting & diarrhea. Nausea. Unusually high heart rate of 176. Slight confusion. Erratic speech. Involuntary muscle contractions. All symptoms lasting around 3.5 hours. Body temp lower than usual for a few hours.
Tinnitus   Most notably in my left ear.  Continuous beginning a few hours after the injection and has not stopped
injection site pain, tiredness, headache, joint pain in knees, chills, nausea , feeling unwell week and dizzy
2 hours after injection the arm became quite painful, swollen, red, hard - lasted approx 2 days.
Fatigued for 12-24 hours. Sore arm at injection site for 48 hours.
12/4/21 Moderna booster injection. 12/16 burning, red rashes all over with itching symptoms. Thereafter raised skin. Reported to Dr. on 12/22 and 12/23, nurse recommended Zyrtec and topical cream/lotion or hydrocortisone application. Relief strategy helps stop burning, itching and raised skin. But, red rash continue. If relief strategy is paused, then within a day, all adverse events reappear
We have some Moderna Covid-019 vaccine that was given after the expiration date.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (We have some Moderna Covid-019 vaccine that was given after the expiration date.) in a 64-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 091D21A) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 03-Nov-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (We have some Moderna Covid-019 vaccine that was given after the expiration date.). On 03-Nov-2021, EXPIRED PRODUCT ADMINISTERED (We have some Moderna Covid-019 vaccine that was given after the expiration date.) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.    Date the vial was initially stored in the refrigerator 24- Sept-2021. Date  of administration of vaccine 24Oct2021 - 27Oct2021 No concomitant medications was reported. no treatment was reported.
The report was first received from a practice manager on 07-SEP-2018, and it was recognized as non-valid because report did not obtain any patient identify. Follow-up information has been received from the practice manager on 18-SEP-2018. This spontaneous report refers to a patient of unknown age and gender. Information of concurrent condition, medical history and concomitant therapy was not provided. On 09-OCT-2017, the patient was vaccinated with an improperly stored dose of PROQUAD (recombinant Human albumin) (strength and route were unknown) (lot # N013863 and expiration date 31-OCT-2018) for prophylaxis. The sterile diluent (MERCK) was properly stored. No adverse event was reported. The excursion temperature on 22-SEP-2017, 17-OCT-2017, 06-DEC-2017, 07-DEC-2017, 30-JAN-2018, 23-FEB-2018, 18-MAY-2018, 05-JUL-2018, 15-AUG-2018 was 6 degree Celsius for maximize 8.75 hours. The excursion temperature on 02-MAR-2018, 27-AUG-2018 was 7 degree Celsius for maximize 8.75 hours. The excursion temperature on 07-DEC-2017 was 8 degree Celsius for maximize 15 hours. The call was not because of data logger. This is one of several reports received from the same reporter. Sender's Comments: US-009507513-1809USA003709: US-009507513-1810USA001951: US-009507513-1810USA001952: US-009507513-1810USA001953: US-009507513-1810USA001954: US-009507513-1810USA001955: US-009507513-1810USA001956: US-009507513-1810USA001957: US-009507513-1810USA001959.
Information has been received from a consumer concerning her 21 year old female daughter allergic to codeine and a history of flu and bronchitis who on 25-MAR-2007, 21-NOV-2007, and 27-MAR-2008 was vaccinated with a dose of GARDASIL respectively (Lot number provided with unspecified information corresponds to each patient as below: 659437/1266U; 657736/0389U; 659182/1757U; 656051/0244U; 657617/0384U). Concomitant therapy included YAZ birth control previously and switched to new unspecified birth control. The mother had a list of the lot numbers and dates of administration, however she was unsure of which dates corresponded to this patient. The information she had came from a doctor's office where the patient received the vaccines. On an unspecified date, the patient experienced two abnormal pap smears and was scheduled for a third pap smear to determine current status. The patient sought medical attention. Laboratory diagnostics studies included a yearly physical in August 2010, results not reported. No treatment for the adverse event was given, however close monitoring was being executed. If the patient continued to receive abnormal pap smear results, it had been suggested that she had her cervix frozen through an in-office procedure. At the time of the report the patient was not recovered. This is one of two reports received from the same source. Additional information has been requested.
Emergency room, many tests to rule things out and told to take supplements Vitamin D3 MK7, Vitamin C, Opti-Zinc.  Also did the AIP diet protocol for about 3 weeks and now starting to add foods back in.  It's been 8 weeks and I'm just now starting to feel a little more like myself with a little more energy.
photosensitivity reaction; face was terrible red; progressively worse; very sore arm; red blotchy spot at the injection site; chills; very tired; muscle aches; aches; red blotchy spot in her face/ neck/ chest; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (red blotchy spot in her face/ neck/ chest), PHOTOSENSITIVITY REACTION (photosensitivity reaction), ERYTHEMA (face was terrible red), PAIN (aches) and CONDITION AGGRAVATED (progressively worse) in a 60-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 02921A and 039K20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event. Concomitant products included ALENDRONATE SODIUM (FOSAMAX) for an unknown indication.   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Mar-2021, the patient experienced RASH MACULAR (red blotchy spot in her face/ neck/ chest), PAIN (aches), PAIN IN EXTREMITY (very sore arm), VACCINATION SITE ERYTHEMA (red blotchy spot at the injection site), CHILLS (chills), FATIGUE (very tired) and MYALGIA (muscle aches). On 15-Mar-2021, the patient experienced CONDITION AGGRAVATED (progressively worse). On an unknown date, the patient experienced PHOTOSENSITIVITY REACTION (photosensitivity reaction) and ERYTHEMA (face was terrible red). On 15-Mar-2021, PAIN (aches), PAIN IN EXTREMITY (very sore arm), CHILLS (chills) and MYALGIA (muscle aches) had resolved, FATIGUE (very tired) outcome was unknown. At the time of the report, RASH MACULAR (red blotchy spot in her face/ neck/ chest), PHOTOSENSITIVITY REACTION (photosensitivity reaction), ERYTHEMA (face was terrible red), CONDITION AGGRAVATED (progressively worse) and VACCINATION SITE ERYTHEMA (red blotchy spot at the injection site) outcome was unknown. Not Provided      For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No concomitant medications were reported.  No laboratory details were  provided.  Treatment Prednisone for two weeks, a steroid cream for her face, 3 mg Benadryl 3 times a day for two week   This case was linked to MOD21-058418 (E2B Linked Report).; Sender's Comments:  MOD21-058418:Cross-Linked Case
Vomiting, diarrhea- three or four days then a break and returns for several days - been going on for 5 months
Noticed numbness to L upper extremity and L lower extremity by the evening after receiving the HBV vaccine in the morning.
Sleepiness; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of SOMNOLENCE (Sleepiness) and FATIGUE (Tiredness) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039k20A and 039k20A) for COVID-19 vaccination.     No medical history was provided by the reporter.    On 17-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Feb-2021, the patient experienced SOMNOLENCE (Sleepiness) and FATIGUE (Tiredness). At the time of the report, SOMNOLENCE (Sleepiness) and FATIGUE (Tiredness) outcome was unknown.            Concomitant product used included cholesterol medication NOS.  Treatment information was not provided.
Severe swelling at injection site, felt "hot" to the touch. Swelling continued for 3 days.
fever; pain behind the eyes; headache; nausea; swelling in the arm; fatigue; pain at the injection site; This case was reported by a physician via call center representative and described the occurrence of fever in a 17-year-old male patient who received Men B NVS (Bexsero) for prophylaxis.   On 17th September 2020, the patient received the 2nd dose of Bexsero. On 18th September 2020, 1 days after receiving Bexsero, the patient experienced fever, pain behind eyes, headache, nausea, swelling arm, fatigue and injection site pain. On 18th September 2020, the outcome of the fever, pain behind eyes, headache, nausea, swelling arm, fatigue and injection site pain were recovered/resolved.   It was unknown if the reporter considered the fever, pain behind eyes, headache, nausea, swelling arm, fatigue and injection site pain to be related to Bexsero.  Additional details were provided as follows: The age at vaccination was not reported. The patient started with fever, pain behind the eyes, headache, nausea, swelling in the arm, fatigue and pain at the injection site but they all were transient and by the afternoon they were gone (as reported)but at the afternoon they were gone.  The reporter consent to follow up.
Itchy bumps 1 on back, 1 on arm, 1 on leg.
Fever, seizure.  My spouse found me in bead around 1am shaking uncontrollably and unconscious.  She attempted to wake me for several minutes.  When I woke I was still shaking and unaware of my surroundings.  I was sweating profusely and had a very painful headache.  Throughout the next day, Feb 9 I was extremely exhausted and lethargic.   I feel asleep while eating and while showering, similar to my reaction to the first dose.
Employee states the vaccine "bothered her heart" and she was in the ER, then discharged same day.
sz x 3; @ approx 1 PM pt eyes bulged out worse than a Pekingese, became very glassy, face turned red then blue, tongue stuck out of mouth, mouth clamped down tight on tongue, head began bobbing, turned grey, 3rd episode pt limp & fatigued;
Patient received 1st dose MMR vaccine at another clinic.  1 hr later she started vomiting.
Resting heart rate was 122. Decreased to 95 by 11:30.  Normal next morning.
arm  hurts; Initial information received on 10-Oct-2020 regarding an unsolicited valid non-serious case received from a consumer or non-healthcare professional via social media.  This case involves female patient experienced arm hurts (pain in extremity), while she received vaccine INFLUENZA VACCINE.  The patient's medical history, past medical treatment, vaccination, concomitant medication and family history were not provided.   On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE (produced by unknown manufacturer) lot number not reported via an unknown route at an unknown administration site for prophylactic vaccination.   On an unknown date, the patient developed a non-serious arm hurts (pain in extremity) (unknown latency) following the administration of INFLUENZA VACCINE.  Laboratory details were not reported.   It was not reported if the patient received a corrective treatment.  The event outcome was unknown for pain in extremity.  There will be no information available on the batch number for this case.
Pt was given bivalent covid for first covid immunization. No adverse events known at this time.
24 hours after first shot, started to develop a rash on face and shoulder. It spread over the course of the next day to the entire body and included both ears turning red and swelling up. Skin hot to the touch and slightly numb. Documented progression of redness and rash on face. Went to see doctor approximately 48 hours after initial shot, advised to take Benadryl and if that does not work or if it gets worse to call back. Advised not to take second dose of vaccine as it is likely an allergic reaction.
Information has been received from a consumer concerning her 77 year old husband with neuromuscular disorder and no known drug allergies who in April 2009, was vaccinated with a dose of ZOSTAVAX (Merck) (route and lot number not reported). About a month later, in approximately May 2009, he started to develop a rash on his elbow which then spread all over his body. The patient's wife reported that the patient saw his physician who sent him to a dermatologist who then sent him to have blood test and a biopsy and the patient was diagnosed with bullous pemphigoid. The consumer reported that the patient already had a neuromuscular disorder and was walking with a cane, then to a walker and after receiving ZOSTAVAX (Merck) he could not walk at all and was in a nursing home to do rehab, but because of the rash, the patient could not do the rehab. At the time of reporting, the patient had not recovered from the events. Upon internal review, he could not walk at all was considered to be disabling. No further information is available.
CONFIRMED CLINICAL VACCINATION FAILURE; CONFIRMED COVID-19 INFECTION; REVACCINATION WITH DIFFERENT COVID-19 VACCINE; This spontaneous report received from a patient via other manufacturer (pfizer) concerned a patient of unspecified age, sex, race and ethnicity. The patient's height, and weight were not reported. The patient's concurrent conditions included: diabetes, obesity, and unspecified drug allergy. The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 1) (suspension for injection, route of admin, expiry date and batch number were not reported) dose was not reported, 1 total administered on 18-MAR-2021 for covid-19 prophylaxis. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers.   The patient additionally received non-company suspect vaccine Moderna (elasomeran) (Dose number in series 2) (form of admin, route of admin, expiry date and batch number were not reported) dose was not reported, administered on 17-NOV-2021 at left arm for covid-19 prophylaxis.  It was unknown whether patient had any adverse events following vaccination with non-company suspect vaccine Moderna (elasomeran) (Dose number in series 2) The patient additionally received non-company suspect vaccine Moderna (elasomeran) (Dose number in series 3) (form of admin, route of admin, expiry date and batch number were not reported) dose was not reported, administered on 21-JUL-2022 at right arm for covid-19 prophylaxis which was revaccination with different covid-19 vaccine (Dose number in series 3). Concomitant medications included vitamins.  On unspecified date in 2023, the patient experienced covid-19 infection (confirmed covid-19 infection) (Dose number in series 3) which led to confirmed clinical vaccination failure (Dose number in series 1) and received treatment drug paxlovid from 04-NOV-2023 to 8-NOV-2023 for covid-19. After taking paxlovid for five days, patient tested negative 2 days in a row (09-NOV-2023 and 10-NOV-2023) and then now patient was testing positive and having mild cold symptoms (11-NOV-2023). The action taken with covid-19 vaccine ad26.cov2.s, elasomeran (Dose number in series 2), and elasomeran (Dose number in series 3) was not applicable. The patient was recovering from confirmed covid-19 infection, and the outcome of confirmed clinical vaccination failure and revaccination with different covid-19 vaccine was not reported. This report was serious (Other Medically Important Condition).; Sender's Comments: V0: 20231161671-confirmed clinical vaccination failure . The event has a compatible/suggestive temporal relationship, is unlabeled, and has unknown scientific plausibility. There are other factors more likely to be associated with the event. Specifically: SPECIAL SITUATIONS. Therefore, this event is considered inconsistent with vaccine administration.
Pt is G1P0. At the time she received the vaccine on 1/26/21 she was 13 weeks pregnant. She had normal 1st trimester ultrasound and normal prenatal labs. Her EDD is August 5, 2021.  On 2/9/21 she had a spontaneous miscarriage. No subsequent complications. No history of drug or alcohol abuse. No s/sx of other causes of a early 2nd trimester miscarriage. Of note the 1st trimester genetic testing was unable to be performed due to low fetal free cell DNA when she was at 10w. We were in the process of repeating the labs when the miscarriage happened.  No history of COVID infection, no s/sx of COVID infection at the time of the miscarriage or subsequently. She was not tested.
I received my 4th COVID-19 dose of Moderna on 09/19/2022. My adverse event started on 11/25/2022. In the evening I  had a sore throat, slight fever, cough and a lot of fatigue. I had brain fog and I didn't feel normal. I contacted my doctor on Sunday 11/27/2022. She prescribed me with PAXLOVID. For last 4 days I've been having a moderate headache. Which isn't going away. I spoke with my doctor again she said it was part of COVID-19 symptoms and it will go away eventually. Due to headache I also felt nauseated. Now I am recovering from my COVID-19 infection.
Excessive crying for > 3 hrs. Marked swelling and redness of right outer thigh.
This spontaneous report was received from a other health professional referring to unspecified patients of unknown age and gender. On an unknown date the patients were vaccinated with GARDASIL intramuscular after being improperly stored at 33F (for an unspecified amount of time, dose not reported). No other concomitant therapies reported. No adverse effects reported. The outcome of the event was unknown. The case has been linked with the cases (same reporter link 1406USA008470, 1406USA008158, 1406USA008476 and 1406USA008477. Additional information is not expected.
Information has been received from a registered nurse concerning a 77 year old male with unspecified medical history who on 11/4/2005 was vaccinated with Pneumococcal 23v polysaccharide vaccine (0.5 ml) (lot 650329/0747P), intramuscularly in the right arm. Concomitant therapy included unspecified medication. Subsequently the patient had a swollen, red, right arm, no fever. The patient was seen in the doctors office. The patient was diagnosed with cellulitis and was treated with oral antibiotics, The patient was considered to be doing well. The reporter considered the patients experience to be disabling. It was also reported that two other patients experienced cellulitis after being vaccinated with Pneumococcal 23v polysaccharide vaccine (WAES0511USA02279 and WAES0511USA02280). The reporting nurse requested a lot check. Additional information has been requested.
This spontaneous report as received from a nurse refers to unknown patient of unknown age and gender. The nurse reported that an unknown number of doses of GARDASIL (lot#, dose, route not reported) that were exposed to temperatures between 34F and 35F for 13 hours may have been administered to the unknown patient on an unknown date. Concomitant medications were not provided. No adverse effect was reported. Additional information has been requested.
A 79-year-old female patient reports pre-atrial lymphadenopathy on the left side and redness of the chest and neck 3 days after receiving the Moderna bivalent vaccine.
placing the Shingrix vaccine in the freezer by error; This case was reported by a pharmacist via call center representative and described the occurrence of incorrect storage of drug in a patient who received Herpes zoster (Shingrix) (batch number GL79C, expiry date 13th November 2022) for prophylaxis.   On 16th June 2021, the patient received Shingrix. On 16th June 2021, unknown after receiving Shingrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix ,which was stored in freezer, which led to incorrect storage of drug. No further events were reported. The reporter consented to follow up.
Vaso-vagal Syndrome - Patient recovered well - 2-3 mins after receiving 2 inj. - Patient fell to floor - eyes open - staring - not immediately responsive. Skin, pale, warm, dry. Patient started responding approx 5-10 seconds with full mobility and cognition. 24 hrs after incident - mom disclosed patient had same reaction after MMR in 2003 - She marked "No" on screening form.
This spontaneous report was received from a female consumer concerning her 5 year old son with no pertinent medical history and drug reactions/allergies who on an unknown day in August 2008 was vaccinated with a dose of MMR II (route, lot number and expiration date were not provided), included (Merck) VARIVAX (route, lot number and expiration date were not provided), diphtheria toxoid, pertussis acellular vaccine (unspecified) (manufacturer unknown) (route, lot number and expiration date were not provided), and poliovirus vaccine inactivated (unspecified) (manufacturer unknown) (route, lot number and expiration date were not provided). No concomitant medications were reported. The consumer reported that her son experienced grandmal seizures after being given the vaccines. On an unknown date, a MRI and an EEG were performed (result not provided). The patient sought medical attention, therefore, he did not received any treatment for the event. On an unknown date, the patient had recovered from the event. The relatedness for grandmal seizures was unknown for all the vaccines given in August 2008. This is one of several reports received from the same source (other case number 1301USA007397). Upon internal review, the event of grandmal seizures was considered to be another important medical event. Additional information has been requested.
Received a booster 0.2ml of undiluted Pfizer vaccine for ages 5-11.  Child has already received 2 dose series.   Family notified and will symptom monitor.
Erythema and induration at the injection site started fairly soon after the vaccination (same evening). Kept getting worse over 8 days. Axillary lymphadenopathy started 7 days later. The lymph nodes are tender and it hurts to raise the arm.